Glimehexal (Glimepiride)

Glimehexal is indicated for the oral treatment of type 2 diabetes mellitus when diet, exercise, and other antidiabetic agents do not achieve target glycemic control.

• Used as monotherapy in patients newly diagnosed with type 2 diabetes who cannot tolerate metformin.
• Added to metformin therapy when additional glucose lowering is required.
• May be combined with other oral agents such as DPP‑4 inhibitors or SGLT2 inhibitors under physician supervision.
• Intended for adult patients; not approved for use in children or adolescents.
• Helps reduce fasting and post‑prandial blood glucose levels as part of a comprehensive diabetes management plan.

The safety profile of Glimehexal includes a range of adverse effects that vary in frequency and severity.

Common

• Mild hypoglycemia, especially when meals are skipped or delayed.
• Nausea or abdominal discomfort.
• Headache or dizziness.
• Weight gain due to increased insulin activity.
• Transient fatigue.
• Blurred vision.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions such as skin rash, itching, or angioedema.
• Hepatotoxicity.
• Blood dyscrasias (e.g., leukopenia).

Before prescribing Glimehexal, clinicians should evaluate several patient‑specific factors to minimize risks.

• Assess renal and hepatic function; dose adjustments may be needed in impairment.
• Review history of cardiovascular disease, as sulfonylureas can affect cardiac ischemic preconditioning.
• Use caution in elderly patients due to increased susceptibility to hypoglycemia.
• Avoid use during pregnancy and lactation unless benefits outweigh risks; safety data are limited.
• Monitor blood glucose closely when initiating therapy or changing dose.
• Consider contraindication in patients with known hypersensitivity to sulfonylureas.
• Evaluate for concomitant use of alcohol, which can potentiate hypoglycemia.

Glimehexal can interact with other medicines, altering its effectiveness or increasing the risk of adverse events.

Avoid

• Concurrent use with other sulfonylureas or meglitinides, which may cause additive hypoglycemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can raise glimepiride plasma levels.
• Disulfiram‑containing products, as they may increase the risk of severe hypoglycemia.

Use with caution

• Beta‑blockers, which can mask hypoglycemia symptoms.
• Thiazide diuretics, which may reduce glucose‑lowering efficacy.
• ACE inhibitors or ARBs, requiring monitoring of renal function and electrolytes.
• Alcohol consumption, which can unpredictably affect blood glucose.